{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:23:57Z","timestamp":1772166237840,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T00:00:00Z","timestamp":1694217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T00:00:00Z","timestamp":1694217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["2D43TW009343-06"],"award-info":[{"award-number":["2D43TW009343-06"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43TW009771"],"award-info":[{"award-number":["D43TW009771"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Uganda Ministry of Health issued restrictive guidelines on the use of dolutegravir (DTG) in persons stratified to have a heightened risk of diabetes mellitus. This followed multiple reports of persons with HIV (PWH) presenting with accelerated hyperglycemia after a few weeks to months of exposure to DTG. Having demonstrated a low incidence of diabetes mellitus and improving blood glucose trajectories in a cohort of ART na\u00efve Ugandan PWH on DTG, we sought to determine whether the observed improvement in blood glucose did not mask background compensated insulin resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this analysis, 63 patients underwent serial oral glucose tolerance tests over 48 weeks. Using fasting serum insulin and glucose, we calculated insulin resistance and pancreatic beta cell function by homeostatic modelling (HOMA IR and HOMA%\u03b2 respectively). Absolute mean changes between baseline and post-baseline blood glucose, pancreatic beta cell function and insulin resistance were computed by subtracting each post-baseline value from the baseline value and compared using student t-test. Multiple linear regression models were used to determine the factors associated with changes in pancreatic beta cell function and insulin resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 63 participants, 37 (58%) were female. Median age was 31 (IQR: 28\u201337). Despite a trend towards an initial increase in both HOMA IR and HOMA%\u03b2 at 12 weeks followed by a decline through 36 weeks to 48 weeks, the HOMA IR and HOMA%\u03b2 at 48 weeks were not significantly different from baseline i.e. (difference in mean HOMA IR from baseline: 0.14, 95%CI: -0.46, 0.733, p\u2009=\u20090.648) and (difference in mean HOMA %\u03b2 from baseline: 6.7, 95%CI: -13.4, 26.8, p\u2009=\u20090.506) respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We demonstrated insignificant changes in both insulin resistance and pancreatic beta cell function in clinically stable young adult Ugandan PWH on dolutegravir for 48 weeks. We add to the body of evidence demonstrating glucose metabolic safety of dolutegravir in ART na\u00efve patients. Ugandan guidelines should reconsider restricting DTG initiation in ART naive adults at high risk for diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-023-00564-6","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T02:01:38Z","timestamp":1694224898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults"],"prefix":"10.1186","volume":"20","author":[{"given":"Frank","family":"Mulindwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nele","family":"Brusselaers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Nabwana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bollinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Buzibye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Laker","family":"Agnes Odongpiny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Kiguba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,9]]},"reference":[{"key":"564_CR1","unstructured":"\u201cWHO recommends. Dolutegravir as preferred HIV treatment option in all populations. https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations (Accessed Jul 30, 2022)."},{"key":"564_CR2","unstructured":"\u201cUPDATE OF RECOMMENDATIONS ON FIRST-AND. SECOND-LINE ANTIRETROVIRAL REGIMENS,\u201d 2019."},{"key":"564_CR3","unstructured":"\u201cFact Sheet. : HIV Drug Resistance.\u201d https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drug-resistance (Accessed Mar 13, 2022)."},{"key":"564_CR4","doi-asserted-by":"publisher","unstructured":"Frentz D, et al. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis. Jul. 2014;14(1):1\u201312. https:\/\/doi.org\/10.1186\/1471-2334-14-407\/FIGURES\/2.","DOI":"10.1186\/1471-2334-14-407\/FIGURES\/2"},{"key":"564_CR5","doi-asserted-by":"publisher","unstructured":"Dow DE, Bartlett JA. Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV. Infect Dis Ther. Dec. 2014;3(2):83\u2013102. https:\/\/doi.org\/10.1007\/S40121-014-0029-7\/FIGURES\/2.","DOI":"10.1007\/S40121-014-0029-7\/FIGURES\/2"},{"issue":"3","key":"564_CR6","first-page":"171","volume":"17","author":"M D\u2019Abbraccio","year":"2015","unstructured":"D\u2019Abbraccio M, Busto A, De Marco M, Figoni M, Maddaloni A, Abrescia N. Efficacy and tolerability of integrase inhibitors in antiretroviral-naive patients. AIDS Rev. 2015;17(3):171\u201385.","journal-title":"AIDS Rev"},{"key":"564_CR7","unstructured":"WHO., \u201cWHO policy adoption and implementation status in countries,\u201d 2019."},{"key":"564_CR8","unstructured":"\u201cUpdate on. The transition to Dolutegravir based anti-retroviral therapy, no. March, 2022."},{"key":"564_CR9","doi-asserted-by":"publisher","unstructured":"Twimukye A, et al. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda. BMC Infect Dis. Dec. 2021;21(1):1\u201314. https:\/\/doi.org\/10.1186\/S12879-021-06851-9\/TABLES\/4.","DOI":"10.1186\/S12879-021-06851-9\/TABLES\/4"},{"key":"564_CR10","unstructured":"WHO., \u201cConsolidated guidelines on the use of ARVs.&#8221."},{"key":"564_CR11","doi-asserted-by":"publisher","unstructured":"Lamorde M et al. \u201cDolutegravir-associated hyperglycaemia in patients with HIV,\u201d The Lancet HIV, vol.\u00a07, no. 7. Elsevier Ltd, pp. e461\u2013e462, Jul. 01, 2020. https:\/\/doi.org\/10.1016\/S2352-3018(20)30042-4.","DOI":"10.1016\/S2352-3018(20)30042-4"},{"key":"564_CR12","unstructured":"\u201cMINISTRY OF HEALTH CONSOLIDATED GUIDELINES FOR THE PREVENTION AND TREATMENT OF. HIV AND AIDS IN UGANDA,\u201d 2020."},{"key":"564_CR13","doi-asserted-by":"publisher","unstructured":"Mulindwa F et al. \u201cAssociation between integrase strand transfer inhibitor use with insulin resistance and incident diabetes mellitus in persons living with HIV: a systematic review and meta-analysis,\u201d BMJ Open Diabetes Res Care, vol.\u00a011, no. 1, p. e003136, Feb. 2023, https:\/\/doi.org\/10.1136\/BMJDRC-2022-003136.","DOI":"10.1136\/BMJDRC-2022-003136"},{"key":"564_CR14","doi-asserted-by":"publisher","unstructured":"Mulindwa FI, Kamal H, Castelnuovo B, Bollinger RC, Schwarz J-M, Brussealers N. \u201cAssociation between integrase strand transfer inhibitor (INSTIs) use with insulin resistance and incident diabetes mellitus in persons living with HIV: A systematic review and meta-analysis protocol,\u201d PLoS One, vol.\u00a017, no. 3, p. e0264792, Mar. 2022, https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0264792.","DOI":"10.1371\/JOURNAL.PONE.0264792"},{"key":"564_CR15","doi-asserted-by":"publisher","unstructured":"Mulindwa F, et al. Blood glucose trajectories and incidence of diabetes mellitus in ugandan people living with HIV initiated on dolutegravir. AIDS Res Ther. Mar. 2023;20(1):1\u201311. https:\/\/doi.org\/10.1186\/S12981-023-00510-6\/TABLES\/2.","DOI":"10.1186\/S12981-023-00510-6\/TABLES\/2"},{"key":"564_CR16","doi-asserted-by":"publisher","unstructured":"Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: an overview. Avicenna J Med. Oct. 2020;10(4):174. https:\/\/doi.org\/10.4103\/AJM.AJM_53_20.","DOI":"10.4103\/AJM.AJM_53_20"},{"key":"564_CR17","doi-asserted-by":"publisher","unstructured":"Skyler JS, et al. Differentiation of diabetes by Pathophysiology, Natural History, and prognosis. Diabetes. Feb. 2017;66(2):241\u201355. https:\/\/doi.org\/10.2337\/DB16-0806.","DOI":"10.2337\/DB16-0806"},{"key":"564_CR18","unstructured":"\u201cClinical Biochemistry Department Oral. Glucose Tolerance Test Procedure in Adults\u201d."},{"key":"564_CR19","unstructured":"\u201cBlood Glucose Meters | Accu-Chek. \u201d https:\/\/www.accu-chek.com\/meters (Accessed Aug 27, 2023)."},{"key":"564_CR20","unstructured":"\u201cINS elisa kit |. Human insulin ELISA Kit-AAA59172.1. https:\/\/www.mybiosource.com\/ins-human-elisa-kits\/insulin\/761338 (accessed Aug. 27, 2023)."},{"key":"564_CR21","unstructured":"Health MOF, \u201cMINISTRY OF HEALTH CONSOLIDATED GUIDELINES FOR THE PREVENTION AND TREATMENT OF HIV AND AIDS IN UGANDA., \u201d no. February, 2020."},{"key":"564_CR22","unstructured":"\u201cHOMA Calculator \u2014 Radcliffe Department of Medicine. \u201d https:\/\/www.rdm.ox.ac.uk\/about\/our-clinical-facilities-and-mrc-units\/DTU\/software\/homa (accessed May 30, 2023)."},{"key":"564_CR23","unstructured":"\u201cHOMA Calculator \u2014 Radcliffe Department of Medicine. \u201d https:\/\/www.rdm.ox.ac.uk\/about\/our-clinical-facilities-and-mrc-units\/DTU\/software\/homa (accessed Aug. 27, 2023)."},{"key":"564_CR24","doi-asserted-by":"publisher","unstructured":"Gutch M, Kumar S, Razi SM, Gupta K, Gupta A. Assessment of insulin sensitivity\/resistance. Indian J Endocrinol Metab. Jan. 2015;19(1):160\u20134. https:\/\/doi.org\/10.4103\/2230-8210.146874.","DOI":"10.4103\/2230-8210.146874"},{"key":"564_CR25","doi-asserted-by":"crossref","unstructured":"Curr Diabetes Rev, vol.\u00a010, no. 1, pp.\u00a02\u201342, Mar. 2014, doi: 10.2174\/1573399810666140214093600.","DOI":"10.2174\/1573399810666140214093600"},{"key":"564_CR26","unstructured":"WHO., \u201cGlobal Physical Activity Questionnaire (GPAQ) Analysis Guide,\u201d Geneva: World Health Organization, pp.\u00a01\u201322, 2012."},{"key":"564_CR27","doi-asserted-by":"publisher","unstructured":"Hileman CO, Funderburg NT. Inflammation, Immune activation, and antiretroviral therapy in HIV. Curr HIV\/AIDS Rep. Jun. 2017;14(3):93. https:\/\/doi.org\/10.1007\/S11904-017-0356-X.","DOI":"10.1007\/S11904-017-0356-X"},{"key":"564_CR28","doi-asserted-by":"publisher","unstructured":"Pedro MN, et al. Insulin resistance in HIV-Patients: causes and consequences. Front Endocrinol (Lausanne). Sep. 2018;9:514. https:\/\/doi.org\/10.3389\/FENDO.2018.00514. no. SEP.","DOI":"10.3389\/FENDO.2018.00514"},{"key":"564_CR29","doi-asserted-by":"publisher","unstructured":"Honnapurmath VK, Patil VW. \u201cAntiretroviral therapy-induced insulin resistance and oxidative deoxy nucleic acid damage in human immunodeficiency virus-1 patients,\u201d Indian J Endocrinol Metab, vol.\u00a021, no. 2, pp.\u00a0316\u2013321, Mar. 2017, https:\/\/doi.org\/10.4103\/2230-8210.202029.","DOI":"10.4103\/2230-8210.202029"},{"key":"564_CR30","doi-asserted-by":"publisher","unstructured":"DeFronzo RA, Simonson D, Ferrannini E. \u201cHepatic and peripheral insulin resistance: A common feature of Type 2 (non-insulin-dependent) and Type 1 (insulin-dependent) diabetes mellitus,\u201d Diabetologia, vol.\u00a023, no. 4, pp.\u00a0313\u2013319, Oct. 1982, https:\/\/doi.org\/10.1007\/BF00253736.","DOI":"10.1007\/BF00253736"},{"key":"564_CR31","doi-asserted-by":"publisher","unstructured":"Nolan NS, Adamson S, Reeds D, O\u2019Halloran JA. Bictegravir-based antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus. Open Forum Infect Dis. May 2021;8(5). https:\/\/doi.org\/10.1093\/OFID\/OFAB077.","DOI":"10.1093\/OFID\/OFAB077"},{"key":"564_CR32","doi-asserted-by":"publisher","unstructured":"Kamal P, Sharma S, Supplement_1 no, Apr. 2019, doi: https:\/\/doi.org\/10.1210\/js.2019-sun-187.","DOI":"10.1210\/js.2019-sun-187"},{"key":"564_CR33","doi-asserted-by":"publisher","unstructured":"McLaughlin M, Walsh S, Galvin S. \u201cDolutegravir-induced hyperglycaemia in a patient living with HIV,\u201d Journal of Antimicrobial Chemotherapy, vol.\u00a073, no. 1. Oxford University Press, pp.\u00a0258\u2013260, Jan. 01, 2018. https:\/\/doi.org\/10.1093\/jac\/dkx365.","DOI":"10.1093\/jac\/dkx365"},{"key":"564_CR34","doi-asserted-by":"publisher","unstructured":"Kajogoo VD, Amogne W, Medhin G. New onset type 2 diabetes mellitus risks with integrase strand transfer inhibitors-based regimens: a systematic review and meta-analysis. Metabol Open. Mar. 2023;17:100235. https:\/\/doi.org\/10.1016\/J.METOP.2023.100235.","DOI":"10.1016\/J.METOP.2023.100235"},{"key":"564_CR35","doi-asserted-by":"publisher","unstructured":"Fong PS, Flynn DM, Evans CD, Korthuis PT. \u201cIntegrase strand transfer inhibitor-associated diabetes mellitus: A case report,\u201d International Journal of STD and AIDS, vol.\u00a028, no. 6. SAGE Publications Ltd, pp.\u00a0626\u2013628, May 01, 2017. https:\/\/doi.org\/10.1177\/0956462416675107.","DOI":"10.1177\/0956462416675107"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00564-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-023-00564-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00564-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T16:57:39Z","timestamp":1700326659000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-023-00564-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,9]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1186\/s12981-023-00564-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3175598\/v1","asserted-by":"object"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,9]]},"assertion":[{"value":"16 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval to perform the study was sought from The AIDS Support Organization (TASO) Institutional Review Board (registration number: TASOREC\/051\/2020-UG-REC-009) and the Uganda National Council for Science and technology (Registration number: HS1032ES). Written consent was obtained before enrolment of study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors report no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}